BELNUC September Seminar (Brain Tumors) + Statutes Voting

Brain tumors in the nuclear medicine department: imaging and theranostics.

Glioblastoma appears to be the most aggressive and also, unfortunately, the most frequent primary brain tumor. The worldwide incidence of glioblastoma is less than 10 per 100,000 people and represents approximately 50–60% of gliomas and 15% of all primary brain tumors in adults. A good and fast diagnosis is therefore of utmost importance, and that is where we as a nuclear medicine department play a key role. How can we help our colleagues neurosurgeons, and what is the best way to interpret and analyse 18F-FET-PET/CT images? And can other tracers, such as, 68Ga- Dotatate, be important in the diagnosis of brain tumors?

The recent progress in nuclear medicine development has generated a new promising arsenal for glioblastoma therapy. This has been mainly driven by biotechnologies such as radioimmunotherapy, radiopeptide therapy, and radionanoparticles. We will get a sneak peak into the first experiences with these new targeted therapies.